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Vascular cognitive impairment defines alterations in cognition, ranging from subtle deficits to full-blown de-
mentia, attributable to cerebrovascular causes. Often coexisting with Alzheimer’s disease, mixed vascular
and neurodegenerative dementia has emerged as the leading cause of age-related cognitive impairment.
Central to the disease mechanism is the crucial role that cerebral blood vessels play in brain health, not
only for the delivery of oxygen and nutrients, but also for the trophic signaling that inextricably links the
well-being of neurons and glia to that of cerebrovascular cells. This reviewwill examine how vascular damage
disrupts these vital homeostatic interactions, focusing on the hemispheric white matter, a region at height-
ened risk for vascular damage, and on the interplay between vascular factors and Alzheimer’s disease.
Finally, preventative and therapeutic prospects will be examined, highlighting the importance of midlife
vascular risk factor control in the prevention of late-life dementia.Introduction
Age-related dementia, an irreversible condition resulting in pro-
gressive cognitive decline, has emerged as one of the leading
health problems of our time. Advances in prevention and
healthcare have increased life expectancy and produced a shift
in the burden of disease worldwide. Thus, noncommunicable
diseases, including dementia, have been recognized for the first
time as the major threat to the world population (World Health
Organization, 2012). The World Health Organization estimates
that 35.6 million people live with dementia, a number that is
anticipated to triple by 2050 (World Health Organization, 2012).
Every year 7.7 million new cases of dementia are diagnosed,
imposing a tremendous burden on families and the primary care-
givers, as well as a financial cost to society. Although recent data
suggest a decline in prevalence (Matthews et al., 2013), demen-
tia remains a devastating and costly disease. In the US such cost
has already surpassed that of cancer and heart diseases (Hurd
et al., 2013). The realization of its paramount public health impact
has led nations, including the US, to develop national plans
to cope with dementia and attempt to reduce its devastating
effects (National Alzheimer’s Project Act; Public Law 111-375).
Vascular dementia, a heterogeneous group of brain disorders
in which cognitive impairment is attributable to cerebrovascular
pathologies, is responsible for at least 20%of cases of dementia,
being second only to Alzheimer’s disease (AD) (Gorelick et al.,
2011). Recent clinical-pathological studies have highlighted the
role of cerebrovascular disease, not only as a primary cause of
cognitive impairment, but also as an adjuvant to the expression
of dementia caused by other factors, including AD and other
neurodegenerative pathologies (Gorelick et al., 2011; Schneider
et al., 2007a; Toledo et al., 2013). At the same time, new exper-
imental findings have revealed a previously unrecognized func-
tional and pathogenic synergy between neurons, glia, and
vascular cells (Iadecola, 2010; Quaegebeur et al., 2011; Zlo-
kovic, 2011), providing a new framework to reevaluate how
alterations in cerebral blood vessels could contribute to the
neuronal dysfunction underlying cognitive impairment. These
advances call for a reappraisal of the role of vascular factors in844 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.cognitive health. To this end, the major cerebrovascular causes
of cognitive dysfunction will be briefly reviewed, focusing on
neuropathology, emerging mechanisms, and overlap with neu-
rodegeneration.
Dementia through the Ages
In Alois Alzheimer’s time (1900s), dementia was thought to be
caused predominantly by ‘‘hardening of the arteries’’ (arterio-
sclerotic dementia) (Bowler, 2007; Jellinger, 2006). Vascular
factors were considered a major player in dementia well into
the 20th century, until, in the 1980s, the Ab peptide was identified
as the main component of parenchymal (amyloid plaque) and
vascular (amyloid angiopathy) amyloid deposits, pathological
hallmarks of AD (Glenner and Wong, 1984; Kang et al., 1987).
Shortly after, mutations in the amyloid precursor protein (APP)
gene were identified in familial forms of AD (Bertram and Tanzi,
2008). Since then, the emphasis shifted from vascular dementia
to AD, a process defined as the ‘‘Alzheimerization of dementia’’
(Figure 1) (Bowler, 2007). However, an increasing appreciation
of the impact of cerebrovascular lesions on AD brought to the
forefront the importance of cerebrovascular health in cognitive
function (Esiri et al., 1999; Gold et al., 2007; Snowdon et al.,
1997). Furthermore, community-based clinical-pathological
studies revealed that the largest proportion of dementia cases
have mixed pathology, comprising features of AD (amyloid
plaques and neurofibrillary tangles) as well as ischemic lesions
(Launer et al., 2008; Schneider et al., 2009). These developments
have promoted an interest to gain a better understanding of
how vascular brain lesions affect cognition and how vascular pa-
thology and neurodegeneration interact to amplify their respec-
tive pathogenic contribution.
Defining Dementia on Vascular Bases:
From Arteriosclerotic Dementia to Vascular
Cognitive Impairment
The concept of dementia caused by cerebrovascular pathology
has evolved considerably over the years (Figure 2). For many
decades vascular dementia was attributed to sclerosis of
Figure 1. Changing Views about Dementia through the Years
In the early 1900s vascular factors were thought to be the main cause of
dementia. Over the next several decades Alzheimer’s disease was felt to be
the main cause. Clinical-pathological studies have revealed that mixed
dementia, combining features of vascular dementia and AD, is currently the
most common cause of cognitive impairment in the aged.
Figure 2. Evolution of the Concept of Cognitive Impairment on
Vascular Bases
Hardening of the arteries was considered the main cause in the early 1900s.
The concept of multi-infarct dementia introduced the possibility of preventing
dementia by controlling vascular risk factors. The introduction of brain imaging
modalities (computer tomography, then magnetic resonance imaging) led to
the realization that white matter disease, termed leukoaraiosis, was a major
cause of cognitive impairment. In the 1990s the term VCI was introduced
to broaden the spectrum of cognitive deficits caused by vascular factors. At
this time, genetic causes of vascular damage causing dementia were also
discovered, CADASIL being the first monogenic cause of vascular cognitive
impairment, identified by M.-G. Bousser and colleagues.
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atrophy (Jellinger, 2006). The first significant departure from
this concept, inspired by the work of Tomlinson and colleagues
(Tomlinson et al., 1970), was proposed by Hachinski and
colleagues (Hachinski et al., 1974), who suggested that demen-
tia on vascular bases was caused by multiple and discrete
ischemic lesions in patients with vascular risk factors, such as
hypertension (multi-infarct dementia) (Figures 2 and 3). The
construct of multi-infarct dementia, by attributing cognitive
impairment to multiple strokes, raised the possibility that pre-
venting cerebrovascular diseases could also prevent dementia
(Hachinski et al., 1974). The introduction of brain imaging led
to the realization that diffuse white matter lesions, termed leu-
koaraiosis (Hachinski et al., 1987), were a frequent correlate of
cognitive impairment, much more common than multiple in-
farcts, which turned out to be a rare cause of dementia (Hulette
et al., 1997) (Figures 2 and 3). Genetic causes of white matter
lesions were discovered, the prototypical one being the Cerebral
Autosomal Dominant Arteriopathy with Subcortical Infarcts and
Leukoencephalopathy (CADASIL) (Chabriat et al., 2009). In the
early 1990s the criteria for diagnosis of vascular dementia
were largely based on those used for AD, which emphasized
memory impairment, irreversibility of the deficits, and impaired
activities of daily living (Roma´n et al., 1993). This definition
was felt to be restrictive since it did not take into due consider-
ation cognitive deficits more commonly associated with cere-
brovascular lesions, such as executive dysfunction and psycho-
motor slowing (Table S1). Therefore, the term vascular cognitive
impairment (VCI) was introduced to better reflect the full range of
cognitive alterations resulting from vascular factors (Hachinski
and Bowler, 1993) (Figure 2). By doing so, it was hoped that
the vascular nature of the cognitive deficit could be recognized
early, providing the opportunity to slow down disease progres-
sion by controlling vascular risk factors (Hachinski and Bowler,
1993). The concept of VCI has gained wide acceptance and is
currently defined as ‘‘a syndrome with evidence of clinical stroke
or subclinical vascular brain injury and cognitive impairmentaffecting at least one cognitive domain’’ (Gorelick et al., 2011),
vascular dementia being the most severe form of VCI.
The Neurovascular Unit: Blood Flow Regulation
and Beyond
The fundamental role that cerebral blood vessels play in the
broad spectrum of pathologies underlying cognitive impairment
highlights the importance of vascular structure and function in
brain health. Owing to its high energy needs and lack of fuel
reserves, the brain requires a continuous and well-regulated
supply of blood (Iadecola, 2004). Most energy is used by neurons
to fuel ionic pumps to maintain and restore the ionic gradients
dissipated by synaptic activity (Harris et al., 2012). Due to fewer
synapses, white matter energy usage, and consequently blood
flow, is 1/3 lower of that of the gray matter (Harris and Attwell,
2012). The brain vasculature has an intimate developmental,
structural, and functional relationship with the brain tissue,
their cellular elements forming a functional domain termed the
neurovascular unit (Iadecola, 2004). Due to their intimate asso-
ciation with brain cells, cerebral blood vessels have unique
characteristics that set them apart from vessels in other organs
(Abboud, 1981; Bevan, 1979; Quaegebeur et al., 2011). The
salient structural and functional features of the cerebral circula-
tion are briefly examined next.
The Brain Vascular Network and Neurovascular Unit
The brain is supplied by arteries arising from the circle of Willis,
a polygon of interconnected vessels at the base of the brain
formed by the confluence of the internal carotid arteries and
the basilar artery (Figure 4). The main vessels arising from the
circle of Willis—the anterior middle and posterior cerebral
arteries, and their branches—give rise to a rich anastomotic
network on the brain surface (pial arteries and arterioles). Pial
vessels are endowed with a smooth muscle cell coat, which sur-
rounds a monolayer of endothelial cells (Figure 4). Pial arterial
branches dive into the brain substance, giving rise to smaller
arterioles still surrounded by an extension of the subarachnoid
space filled with cerebrospinal fluid (perivascular space or
Virchow-Robin space) (Figure 4). Delimited by the vascular
basement membrane and the basement membrane of the glia
limitans (Figure 4) (Dyrna et al., 2013), the perivascular spaceNeuron 80, November 20, 2013 ª2013 Elsevier Inc. 845
Figure 3. Brain Lesions Responsible for
Vascular Cognitive Impairment
All MRI sequences are diffusion-weighted imag-
ing, except for the white matter lesions, which is a
fluid attenuated inversion recovery sequence.
Images are courtesy of Dr. Hooman Kamel.
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proteins and peptides, e.g., Ab (Carare et al., 2013; Iliff et al.,
2013; Laman and Weller, 2013). As intracerebral arterioles reach
deeper into the brain parenchyma and become smaller (diameter
< 100 mm), the perivascular space disappears and the vessel’s
basement membrane enters in direct contact with the glial
basement membrane enveloping the end-feet of astrocytes
(Figure 4). In capillaries, smooth muscle cells are replaced by
pericytes, contractile cells that are particularly abundant in
brain vessels and are involved in the development and mainte-
nance of the BBB (Armulik et al., 2010; Bell et al., 2010; Quaege-
beur et al., 2011).
The ‘‘outside in’’ vascularization pattern of the brain differs
from that of other major organs, like the kidney and liver that
are vascularized from the ‘‘inside out,’’ and places key vessels
regulating intracerebral blood flow, the pial arterioles, outside
the brain parenchyma. Consequently, elaborate vascular
signaling mechanisms coordinate changes in vascular diameter
of pial arterioles on the brain’s surface with those of the intrace-
rebral microvasculature (Bagher and Segal, 2011; Iadecola,
2004). Another consequence of this vascular arrangement is
that occlusion of penetrating arterioles or venules, unlike pial
vessels, cannot be effectively compensated by anastomotic
branches (Blinder et al., 2013), and results in reductions in flow
sufficient to produce small ischemic lesions akin to microinfarcts
(Nguyen et al., 2011; Nishimura et al., 2010; Shih et al., 2013). In
addition, regions of the deep white matter are supplied by long
penetrating arterioles arising from the pial cortical network at
the border between nonoverlapping vascular territories of the
anterior and middle cerebral arteries, and as such are more
vulnerable to reductions in blood flow (Brown and Thore, 2011;
De Reuck, 1971) (Figure 4). On the other hand, the basal ganglia
and brainstem are supplied by penetrating arterioles arising
directly from the circle of Willis and its proximal branches
(Figure 4), rendering these vessels more susceptible to the me-
chanical stresses imposed by chronic hypertension or stiffening
of large arteries (Scuteri et al., 2011; So¨ro¨s et al., 2013).
Neurovascular Control Mechanisms
The brain is endowed with vasoregulatory mechanisms that
assure that it receives enough blood to support the energy needs846 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.of its cellular constituents. Consequently,
neural activity, which uses most of the
brain’s energy budget, is the major deter-
minant of the dynamic regulation of CBF.
The increases in blood flow induced by
activation depend on the concerted ac-
tion of neurons, astrocytes, and vascular
cells through a wide variety of molecular
signals including ions, arachidonic acidmetabolites, nitric oxide (NO), adenosine, neurotransmitters,
and neuropeptides (Drake and Iadecola, 2007). The hemody-
namic changes underlying the increases in blood flow are
mediated by vasoactive agents with opposing vascular actions
(vasodilatation or vasoconstriction), generated by synaptic
activity, astrocytes, interneurons, and afferent projections
from the basal forebrain and brainstem (Cauli and Hamel,
2010; Drake and Iadecola, 2007; Kleinfeld et al., 2011). These
highly coordinated signals converge on specific sites of the
cerebrovascular network to shape the hemodynamic response
to neural activation with a remarkable degree of spatial and
temporal precision (Iadecola, 2004). Thus, the regional hemo-
dynamic changes induced by activation are widely used to
localize neuronal activity in the living brain using functional
imaging (Attwell and Iadecola, 2002).
Like in other organs, endothelial cells regulate vascular tone
by releasing vasoactive factors in response to chemical signals,
e.g., transmitters (Andresen et al., 2006), or mechanical forces,
e.g., shear stress (Ando and Yamamoto, 2013). Unlike other
organs, cerebral endothelial cells in most brain regions are
adjoined by intricate junctional complexes formed by occludins
and claudins (tight junctions) that prevent the bidirectional
exchange of hydrophilic substances between blood the brain,
a key feature of the BBB (Dyrna et al., 2013). Rather, specialized
transport proteins on the endothelial cell membrane control the
traffic of solutes in and out of the brain. For example, GLUT1
and aminoacid transporters regulate the transfer of glucose
and aminoacids into the brain, whereas ‘‘efflux transporters,’’
such as LRP-1, ABC transporters, and others, remove drugs
and metabolic by-products from the brain, including Ab and
lactate (Neuwelt et al., 2011).
Vascular smooth muscle cells, owing to their ability to
constrict when intravascular pressure increases (myogenic
tone), adjust vascular tone in response to changes in arterial
pressure to maintain CBF relatively constant within a range of
pressures (cerebrovascular autoregulation) (Cipolla, 2009).
Autoregulation protects cerebral blood vessels from the wide
swings in arterial pressure associated with the activities of
daily living and provides a stabile CBF baseline on which the
dynamic changes induced by neurovascular coupling and
endothelium are superimposed. These neurovascular control
Figure 4. Anatomy of the Cerebral Blood
Supply
(A) Circle of Willis.
(B) The arterial supply of the deep white matter
arises frombranches of the ACA and theMCA. The
supply of the basal ganglia white matter is pro-
vided by arteries arising directly from the circle of
Willis and its proximal branches. Abbreviations:
ACA: anterior cerebral artery; ICA: internal carotid
artery; MCA: middle cerebral artery; PCA: poste-
rior cerebral artery.
(C) Anatomy of the wall of arteries, arterioles, and
capillaries.
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sufficient blood flow to meet the metabolic needs of its active
cellular constituents.
Trophic Coupling in the Neurovascular Unit
Neurons, astrocytes, oligodendrocytes, and vascular and peri-
vascular cells are in state of close trophic and metabolic
codependence that plays a defining role in brain development,
function, and reaction to injury. In the developing nervous sys-
tem, prototypical neural guidance signals, ephrins, netrins, slit
glycoproteins, and semaphorins also contribute to endothelial
tip cell guidance (Carmeliet and Jain, 2011). In turn, classical
angiogenic molecules, such as VEGF, participate in neurogene-
sis (neurovascular niche), neuronal cellmigration, axonguidance,
dendritogenesis, and oligodendrocyte precursor migration (But-
ler et al., 2010; Carmeliet and Ruiz de Almodovar, 2013; Quaege-
beur et al., 2011). In the adult nervous system, neuroblasts
migrate along blood vessels, a process dependent on BDNF
secretion by endothelial cells (Snapyan et al., 2009). Endothelial
cells have the potential to stimulate the proliferation of neuronal
precursors and to stir their differentiation toward the neuronal
lineage (Shen et al., 2004). Furthermore, through BDNF, insulin
growth factor 2, chemokine (C-X-Cmotif) ligand 12, and pleiotro-
phin, endothelial cells support neuronal survival andprotect them
from injury (Dugas et al., 2008; Guo et al., 2008). Endothelial cells
can also promote the proliferation and survival of oligodendro-
cytes (oligovascular niche) by activating the Akt/PI3 kinase
pathway through BDNF and FGF (Arai and Lo, 2009). In addition
to theirwell-established interactionswith neurons, astrocytes are
also needed for the development andmaintenance of BBB char-
acteristics in endothelial cells (Wolburg et al., 2009) and for the
reorganization of vascular networks after brain injury (Hayakawa
et al., 2012). In turn, endothelial cells regulate glycolytic meta-Neuron 80, Nbolism in astrocytes through the produc-
tion of NO (Brix et al., 2012). Therefore,
neurovascular cells are trophically and
metabolically interdependent, such that
damage to one cell type removes a vital
source of support to the whole unit and
has deleterious consequences also for
the other cell types.
Immune Trafficking and Regulation
The cells of the neurovascular unit are
involved in the initiation and expressionof adaptive and innate immune responses of the brain.
Pericytes and perivascular macrophages have the potential
for antigen presentation, the first step in adaptive immunity,
whereas endothelial cells and microglia are richly endowed
with innate immunity receptors including CD36, toll-like recep-
tors (TLR), and the receptor for advances glycation end-
products (RAGE) (Lampron et al., 2013; Park et al., 2011).
The perivascular space, which drains into the subarachnoid
space and then into cervical lymphnodes (Laman and Weller,
2013), is the ‘‘afferent arm’’ through which brain antigens reach
the systemic immune system (Galea et al., 2007). The cells of
the neurovascular unit also regulate the ‘‘efferent arm’’ of the
immune system, which relies on the transfer of effector immune
cells into the brain. In conditions of hypoxia-ischemia, endo-
thelial cells express adhesion receptors, such as P-selectin,
E-selectin, ICAM, and VCAM, instrumental for the transfer of
circulating leukocytes into the perivascular space (Iadecola
and Anrather, 2011). In turn, perivascular macrophages,
located in contact with the vascular basement membrane, are
required for inflammatory cells, such as lymphocytes, to cross
the glial basement membrane and move from the perivascular
space into the brain parenchyma (Tran et al., 1998). Astrocytes
express ‘‘death’’ ligands (CD95L) on their perivascular end feet
and control immune trafficking by triggering apoptosis of
CD95+ lymphocytes attempting to enter the brain (Bechmann
et al., 1999). Therefore, the neurovascular unit is an important
checkpoint regulating the afferent and efferent arms of the
immune system and shaping the immune responses of the
brain. Vital to vascular homeostasis are circulating endothelial
progenitor cells (EPC), hematopoietic stem cells involved in
the maintenance and repair of endothelial cells (Hill et al.,
2003). EPC development and function is controlled by CD31+
T cells (angiogenic T cells) through the release proangiogenicovember 20, 2013 ª2013 Elsevier Inc. 847
Figure 5. Vascular Lesions Leading to VCI
and Their Effects on the Brain
See text for details. CAA: cerebral amyloid angi-
opathy; ATS: atherosclerosis.
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cells are also involved in the maintenance of vascular homeo-
stasis.
Cerebrovascular Pathologies Underlying Cognitive
Impairment Are Diverse
Considering the vital importance of the cerebral blood supply
for the structural and functional integrity of the brain, it is not
surprising that alterations in cerebral blood vessels have a
profound impact on cognitive function. The vascular alterations
that cause cognitive impairment are diverse, and include
systemic conditions affecting global cerebral perfusion or
alterations involving cerebral blood vessels, most commonly
small size arterioles or venules (Figure 5). Table 1 describes
some of the most common conditions, their vascular bases,
and neuropathological correlates (see Jellinger [2013] for a
more complete list).
Reduced Cerebral Perfusion and Poststroke Dementia
Reduction in global cerebral perfusion caused by cardiac
arrest, arrhythmias, cardiac failure, or hypotension can produce
brain dysfunction and impair cognition transiently or perma-
nently (Table 1) (Alosco et al., 2013; Justin et al., 2013;
Marshall, 2012; Stefansdottir et al., 2013). High-grade stenosis
or occlusion of the internal carotid arteries is associated with
chronic ischemia and can lead to cognitive impairment even
in the absence of ischemic lesions (Balestrini et al., 2013;
Cheng et al., 2012; Johnston et al., 2004; Marshall, 2012)
(Figure 5).848 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.On the other hand, if the reduction in
CBF is sustained and severe, ischemic
stroke ensues (Moskowitz et al., 2010).
Stroke doubles the risk for dementia
(poststroke dementia), and approxi-
mately 30% of stroke patients go on to
develop cognitive dysfunction within 3
years (Allan et al., 2011; Leys et al.,
2005; Pendlebury and Rothwell, 2009).
The association between stroke and de-
mentia is also observed in patients
younger than 50 years, up to 50% of
whom exhibit cognitive deficits after a
decade (Schaapsmeerders et al., 2013).
As mentioned, multiple infarcts, caused
by multiple arterial occlusions over time,
are well known to impair cognition
(multi-infarct dementia), as can a single
infarct located in a brain regions critical
for cognitive function, such as frontal
lobe or thalamus (Table 1) (strategic
infarct dementia) (Figure 3). However,ischemic strokes are often associated with many of the vascular
pathologies described below, which also contribute to the total
vascular burden.
Small Vessel Disease, Leukoaraiosis,
and Lacunar Infarcts
By far, the most prevalent vascular lesions associated with VCI
are related to alterations in small vessels in the hemispheric
white matter (Jellinger, 2013). These microvascular alterations
result in different neuropathological lesions, which can occur
in isolation but,more typically, coexist in the samebrain (Table 1).
Confluent white matter lesions, the imaging correlate of which
is termed leukoaraiosis (Figure 3), and lacunes, small (<1.5 cm)
white matter infarcts typically in the basal ganglia, are common
occurrence in VCI and are strongly associated with cardiovascu-
lar risk factors, especially hypertension, diabetes, hyperlipid-
emia, and smoking (Gorelick et al., 2011; Wardlaw et al.,
2013a, 2013b). The vascular pathologies underlying these le-
sions consist of atherosclerotic plaques affecting small cerebral
vessels, deposition of a hyaline substance in the vascular wall
(lipohyalinosis), fibrotic changes in the vessel wall resulting in
stiffening and microvascular distortion (arteriolosclerosis), and
total loss of integrity of the vascular wall (fibrinoid necrosis)
(Figure 5) (Thal et al., 2012). Arterioles become tortuous,
have thickened basement membranes, and are surrounded
by enlarged perivascular spaces (Brown and Thore, 2011).
Capillaries are reduced in number and ‘‘string vessels,’’ nonfunc-
tional capillaries that have lost endothelial cells and have only a
basement membrane, are observed (Brown and Thore, 2011).
Table 1. Selected Causes of Cognitive Impairment Related to Vascular Factors
Condition
Predominant
Association/Cause
Target Vessel and
Vascular Pathology
Resulting Brain
Lesions References
Hypoperfusion
dementia
d Cardiac arrest/failure
d Hypotension
d Carotid occlusion
d Large vessel ATS
d Vascular stiffening
d ‘‘Watershed’’ infarcts
d Cortical laminar necrosis
d Incomplete white
matter infarcts
Jellinger, 2013;
Johnston et al., 2004;
Marshall et al., 2012
‘‘Strategic infarct’’
dementia
d Arterial occlusion d Large-medium size arteries d Infarct in regions involved
in cognition, e.g.,
frontal lobe, thalamus, etc.
Jellinger, 2013
Multiinfarct dementia d Multiple arterial
occlusions
(embolic thrombotic)
d Large-medium size
arteries and arterioles
d Multiple large infarcts
d Lacunar infarcts
d Microinfarcts
Thal et al., 2012
White matter lesions
(Leukoaraiosis)
and lacunes
d Vascular risk factors
d CADASIL and other
genetic causes
d Arterioles (<300 mm Ø)
d Small vessel ATS
d Arteriolosclerosis
d Lipohyalinosis
d Venous collagenosis
d Axonal damage
d Demyelination
d Lacunar infarcts
d Microinfarcts
d Microbleeds
Black et al., 2009;
Brown and Thore, 2011;
Thal et al., 2012
Microinfarcts d CADASIL
d CAA, AD
d Vascular risk factors
d Arterioles (<300 mm Ø)
d Small vessel ATS
d Arteriolosclerosis
d Infarcts not visible
by naked eye
Smith et al., 2012
Microbleeds and
hemorrhages
d CAA, AD
d CADASIL
d Vascular risk factors
d Arterioles (<300 mm Ø)
d Vascular rupture
d Small hemorrhage in
perivascular space
d Lobar or basal ganglia
hemorrhage
Charidimou et al., 2012;
Henskens et al., 2008
CADASIL d Notch 3 mutations d Arterioles (<300 mm Ø)
d Thickened wall
d Smooth muscle cell GOM
d Pericyte loss
d White matter lesions
d Lacunar infarcts
d Microinfarcts
d Microbleeds
d Brain atrophy
Chabriat et al., 2009;
Federico et al., 2012;
Schmidt et al., 2012
Cerebral amyloid
angiopathy
d Hereditary
d Sporadic
d AD
d Amyloid deposits in arteries
(<2 mm Ø), arterioles, capillaries
d Smooth muscle degeneration
d Vascular rupture
d Hemorrhage
d White matter lesions
d Microinfarcts
d Microbleeds
Attems et al., 2011;
Charidimou et al., 2012
Poststroke dementia d Ischemic stroke of
any cause
d Large-medium size arteries
d Perivascular immune cells (?)
d Silent infarcts
d White matter lesions
d Lacunar infarcts
d Neuronal loss
d Brain atrophy
Leys et al., 2005;
Iadecola and Anrather,
2011
Mixed AD vascular
dementia
d Sporadic
d Vascular risk factors
d Large-medium size arteries
and arterioles
d AD pathology
d White matter lesions
d Lacunar infarcts
d Microinfarcts
d Microbleeds
Jellinger, 2013;
Thal et al., 2012
Large infarct: > 1 cm Ø; Lacunar infarct: 5–15 mmØ; microinfarct: < 1 mmØ; microbleeds: < 5 mmØ; ATS: atherosclerosis; GOM: graular osmophilic
material; vascular risk factors: hypertension, diabetes, smoking, etc.
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(Black et al., 2009; Brown and Thore, 2011). The white matter
damage resulting from these lesions consists of vacuolation,
demyelination, axonal loss, and lacunar infarcts. The white mat-
ter lesions generally correspond to hyperintensities observed
on MRI, which, however, can also reflect other pathological
substrates (Gouw et al., 2011). The white matter lesions evolve
over time by expansion of existing lesions, rather than formation
of new foci (Maillard et al., 2012), resembling the patterns of
progression of amyloid angiopathy (Alonzo et al., 1998; Robbins
et al., 2006). The expansion of the white matter lesions correlateswith the evolution of the cognitive impairment (Maillard et al.,
2012), new lacunes causing a steeper decline, especially in
motor speed and executive functions (Jokinen et al., 2011).
White matter lesions and lacunar infarcts are also present in
uncommon genetic conditions resulting in VCI and vascular
dementia (Federico et al., 2012; Schmidt et al., 2012). The
better studied of these, CADASIL, is associated with extensive
leukoaraiosis and lacunar infarcts (Chabriat et al., 2009).
CADASIL vascular lesions are related to accumulation of gran-
ular osmiofilic material (GOM) in vascular and perivascular cells,
which include the Notch 3 ectodomain (Yamamoto et al., 2013).Neuron 80, November 20, 2013 ª2013 Elsevier Inc. 849
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Microscopic infarcts (microinfarcts) and hemorrhages (micro-
bleeds) (Figure 5) are independent predictors of cognitive
dysfunction, but are commonly associated with other vascular
pathologies, such as leukoaraiosis, lacunar infarcts, large
infarcts, and hemorrhage (Smith et al., 2012; van Norden
et al., 2013), as well as CADASIL and AD (Table 1). Microin-
farcts are sharply delineated lesions consisting of pallor, necro-
sis, cavitation, and inflammation (astrocytosis, microgliosis,
and macrophage infiltration) (Thal et al., 2012), caused by the
small vessel pathology described above (Table 1). Microbleeds
are microscopic areas of blood extravasation from leaky
arterioles, which are restricted to the perivascular space and
do not disrupt the brain parenchyma (De Reuck, 2012).
Observed in 17% of demented patients (Cordonnier and van
der Flier, 2011), cortical microbleeds are frequently associated
with cerebral amyloid angiopathy (CAA), whereas microbleeds
in deep regions tend to be associated with white matter dis-
ease secondary to vascular risk factors (De Reuck, 2012;
Park et al., 2013a).
Cerebral amyloid angiopathy
It is well known that deposits of Ab in cerebral blood vessels
or CAA are associated with vascular cognitive impairment.
Although inherited forms of CAA have been described, CAA
is most prevalent in AD, being present in over 90% of cases
(Attems et al., 2011; Charidimou et al., 2012). CAA is also
observed in demented (50%–60%) and nondemented
(20%–40%) elderly people (Attems et al., 2011; Charidimou
et al., 2012). The major risk factor for CAA is advanced
age, and cardiovascular risk factors seem to play a lesser
role (Charidimou et al., 2012). CAA is a major cause of micro-
bleeds and large hemorrhages, typically located in the cortex
(lobar hemorrhages) (Auriel and Greenberg, 2012). The amyloid
accumulation occurs in the media and the adventitia of
cerebral vessels, leading to degeneration of smooth muscle
cells and pericytes (Thal et al., 2012). In extreme cases, the
vascular wall develops fibrinoid necrosis and the vessels
assume a characteristic double barrel appearance (Thal et al.,
2012).
Mixed lesions
Overlap of AD neuropathology (amyloid plaques and neuro-
fibrillary tangles) with cerebrovascular lesions is observed in up
to 50% of cases of dementia (Jellinger, 2013). These lesions
include atherosclerosis of the circle of Willis and its branches,
leukoaraiosis, and lacunar infarcts, microbleeds, microinfarcts,
and CAA (Benedictus et al., 2013; Charidimou et al., 2012;
Honig et al., 2005; Jellinger, 2013; Richardson et al., 2012;
Roher et al., 2004; Toledo et al., 2013; Yarchoan et al., 2012).
Ischemic lesions in regions between arterial territories
(watershed infarcts) have also been reported in AD, implicating
hypoperfusion and CAA in their mechanisms (Miklossy, 2003;
Suter et al., 2002). Vascular lesions are also present in
other age-related neurodegenerative diseases, such as synu-
cleinopathies, hippocampal sclerosis, and frontotemporal lobar
degeneration linked to tau or TDP-43, but the coexistence with
AD is the most frequent (Toledo et al., 2013).850 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.How Do Vascular Factors Cause Cognitive Impairment?
As reviewed above, VCI can stem from a wide variety of cardio-
vascular and cerebrovascular pathologies, but it has been diffi-
cult to pin down the contribution of each condition to cognitive
dysfunction because of the coexistence of the different lesions
and overlap with neurodegenerative pathology (Gorelick et al.,
2011). Reductions in global cerebral perfusion, such as those
caused by heart diseases or carotid artery stenosis/occlusion,
if below a critical threshold, can impair cognition independently
of brain lesions (Marshall et al., 2012). Reductions in CBF by
40%–50% are associated with suppression of brain activity
and cognitive dysfunction, which are reversible upon re-estab-
lishing normal CBF levels (Marshall et al., 1999; Marshall, 2012;
Tatemichi et al., 1995). As for the other pathologies underlying
VCI, there is a general correlation between the total burden of
vascular pathology and cognitive deficits (Gelber et al., 2012;
Gorelick et al., 2011; Inzitari et al., 2009). A caveat is that, due
to confounding factors, such as overlap with AD, differences in
educational level (see below), and microscopic pathology not
seen by in vivo imaging, the exact parameters of the relationship
have been hard to define (Black et al., 2009; Brickman et al.,
2011). However, there is general consensus that cognitive
impairment results from the brain dysfunction caused by cumu-
lative tissue damage (Gorelick et al., 2011), as originally pro-
posed by Tomlinson et al. for large cerebral infarcts (Tomlinson
et al., 1970).
In addition to gray matter damage, disruption of the white
matter can have profound effects on the precision and fidelity
of the information transfer underlying brain function and cogni-
tive health (Nave, 2010a). Fast-conducting myelinated white
matter tracts are responsible for long-range connectivity, inter-
hemispheric synchronization, and neurotrophic effects through
spike-timing-dependent plasticity and axonal transport (Dan
and Poo, 2004; Nave, 2010a; Stone and Tesche, 2013). Indeed,
white matter lesions affect brain structure and function broadly
and are associated with reductions in frontal lobe glucose utiliza-
tion (DeCarli et al., 1995; Haight et al., 2013; Tullberg et al., 2004),
global reduction in cortical blood flow (Appelman et al., 2008;
Chen et al., 2013a; ten Dam et al., 2007; Kobari et al., 1990),
disruption of brain connectivity (Lawrence et al., 2013; Sun
et al., 2011), and cerebral atrophy (Appelman et al., 2009). In
addition, since myelination of previously naked fibers partici-
pates in neuroplasticity and skilled motor learning (Fields,
2010; Richardson et al., 2011), myelin damage could also
compromise these important functions and contribute to cogni-
tive impairment.
Risk Factors for Vascular Cognitive Impairments
Ascertaining the genetic and modifiable risk factors of VCI is
problematic due to the multiplicity of underlying pathologies,
coexistence with cardiovascular diseases, and the frequent
overlap with AD and other neurodegenerative diseases (Gorelick
et al., 2011). Therefore, the risk attributable to specific factors
remains unclear, although the recent development of bio-
markers for in vivo AD diagnosis (Hampel et al., 2012) promises
to alleviate this problem.
Advanced age is a powerful risk factor for VCI, and the
prevalence and incidence of cognitive impairment increases
Figure 6. Potential Mechanisms of the
Blood Vessel Damage Induced by Vascular
Risk Factors
Endothelial dysfunction, impairment of autor-
egulation, and dysfunction of neurovascular
coupling, partly mediated by oxidative stress and
NO deficit, reduce CBF resulting in hypoperfusion
and tissue hypoxia. In addition to hypoperfusion,
a critical consequence of endothelial dysfunction
is increased BBB permeability, which leads to
extravasation of plasma proteins, including fibrin-
ogen, into the brain. Fibrinogen activates CD11b
and TLR leading to production of ROS, proin-
flammatory cytokines and MMPs from activated
microglia, reactive astrocytes and OPCs. Inflam-
mation, in turn, aggravates the BBB breakdown
and induces expression of adhesion molecules in
endothelial cells, contributing to leukocyte and
platelet adhesion and microvascular occlusion.
Neuron
Reviewexponentially after age 65 (Gorelick et al., 2011). The level of
education, a surrogate marker of cognitive reserves (Stern,
2012), is an important determinant of the expression of VCI,
such that for a given level of neuropathology higher education
is associated with less cognitive deficits (Zieren et al., 2013).
However, the education level does not influence the rate of
progression of VCI and no longer has an impact in advanced dis-
ease (Elbaz et al., 2013; Zieren et al., 2013). Although education
could account for individual differences in the susceptibility
to cognitive impairment given comparable burdens of disease,
socioeconomic status, coexisting chronic diseases, ethnicity,
and premorbid intellectual capacity are important confounders
(Gorelick et al., 2011).
Vascular risk factors, including hypertension, diabetes, hyper-
lipidemia, smoking, atrial fibrillation, and hyperhomocystinemia,
increase the risk of dementia independently of the associated
increase in stroke risk (Sahathevan et al., 2012). Furthermore,
the metabolic syndrome, including insulin resistance, hyperten-
sion, and dyslipidemia, has been associated with lower cognitive
performance (Yates et al., 2012). However, recurrent stroke is
one of the strongest predictors of dementia onset (Pendlebury
and Rothwell, 2009). Remarkably, in VCI as in AD, the increase
in risk afforded by vascular risk factors is observed decades
later, a finding that may explain why some studies did not find
a cognitive improvement with risk factor control later in life
(Sahathevan et al., 2012).
A host of rare genetic mutations are associated with VCI
(Federico et al., 2012; Schmidt et al., 2012). The most common
of these is the CADASIL syndrome caused by a frame shift
mutation of Notch-3 that either creates or eliminates a cystein
residue (Chabriat et al., 2009). Other hereditary cerebral vas-
culopathies include familial CAAs caused by mutations or
duplications of APP (Auriel and Greenberg, 2012; Rannikma¨e
et al., 2013), the cerebral autosomal recessive arteriopathy
with subcortical infarcts and leukoencephalopathy (CARASIL)
caused by mutation of the TGFb repressor HTRA1, the auto-
somal dominant retinal vasculopathy with cerebral leukodystro-Neuron 80, Nphy caused by frameshift deletions in the
exonuclease TREX1, and mutations of
the COL4A1 gene encoding the type IVcollagen alpha 1 chain (Federico et al., 2012; Gorelick et al.,
2011; Lanfranconi and Markus, 2010). The ApoE 4 allele is a
well-established susceptibility gene for increased cardiovascu-
lar risk and Alzheimer disease (Verghese et al., 2011). The
ApoE4 allele is associated with increased risk of CAA, whereas
both ApoE2 and 4 increase the risk of lobar hemorrhages
(Charidimou et al., 2012). Nevertheless, a strong link between
ApoE and sporadic VCI has not been established (Lee and
Kim, 2013; Yu et al., 2013). Studies of candidate genes have
revealed weak associations with genes involved in the renin-
angiotensin system, endothelial nitric oxide synthase, oxidative
stress, lipid metabolism and inflammation, but have not been
replicated (Fornage et al., 2011; Lee and Kim, 2013; Markus,
2008). GWAS of vascular dementia have shown small effect of
SNPs in the androgen receptor gene locus (Schrijvers et al.,
2012), a finding not observed in all ethnic groups (Lee and Kim,
2013). The diversity of pathologies underlying VCI and the
overlap with AD complicate the interpretation of these studies.
Linkage studies in patients with white matter lesions on MRI
have discovered several loci (Schmidt et al., 2012), but no
specific gene has been identified and the findings await replica-
tion and validation (Lee and Kim, 2013; Markus, 2008).
Pathogenic Mechanisms Responsible for White
Matter Injury
Although as described in the previous section severe ischemia
resulting from arterial occlusion can lead to brain damage and
VCI, e.g., multi-infarct dementia, cognitive dysfunction is most
often associated with more subtle vascular alterations targeting
predominantly the deep hemispheric white matter (Figure 5).
Here we examine the major pathogenic mechanisms leading
to white matter damage, inferred either from brain imaging and
postmortem studies in humans, or animal models (Figure 6).
Hypoperfusion and Hypoxia
Owing to their location at the distal border between different
vascular territories (De Reuck, 1971) (Figure 4) and to theovember 20, 2013 ª2013 Elsevier Inc. 851
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Thore, 2011), deep white matter tracts are particularly vulnerable
to vascular insufficiency. Even in healthy individuals, hypercap-
nia, a potent vasodilator, does not increase, but reduces, CBF
in the periventricular whitematter, suggesting that vasodilatation
of upstream vessels diverts blood flow to other regions (intrace-
rebral steal) (Mandell et al., 2008). This finding highlights the
hemodynamic precariousness of the periventricular white mat-
ter, even in the absence of vascular damage.
Increasing evidence suggests that the white matter cerebral
blood supply is compromised in VCI (Figure 6). Resting flow is
reduced in areas of leukoaraiosis and vascular reactivity attenu-
ated (Kobari et al., 1990; Makedonov et al., 2013; Markus et al.,
2000; 1994; Marstrand et al., 2002; O’Sullivan et al., 2002; Yao
et al., 1992). In patients with VCI risk factors, like hypertension
and diabetes, the ability of neural activity to increase blood
flow in brain or retina is compromised (Delles et al., 2004;
Jennings et al., 2005; Sorond et al., 2011). Cerebrovascular
autoregulation is impaired, increasing the susceptibility of the
white matter to damage during fluctuation in blood pressure
(Matsushita et al., 1994). Interestingly, CBF alterations have
also been described in normal appearing white matter (O’Sulli-
van et al., 2002), suggesting that the flow reduction precedes
and, as such, may contribute to the white matter damage.
Indeed, in the general population, lower global CBF and lower
cerebrovascular reactivity to hypercapnia is associated with a
greater volume of white matter lesions (Bakker et al., 1999;
Vernooij et al., 2008). The CBF reduction is observed prior
to the onset of dementia (Ruitenberg et al., 2005). Due to their
hemodynamic vulnerability, deep white matter regions are
marginally perfused, and, in the presence of vascular risk fac-
tors, their vessels may be unable to adapt CBF to the metabolic
needs of the tissue. Consistent with this hypothesis, postmortem
studies have shown that areas of leukoaraiosis are chronically
hypoxic, as indicated by the expression of hypoxia inducible
factors and related hypoxia-inducible genes (Fernando et al.,
2006; Rosenberg et al., 2001).
In addition to local factors affecting whitematter microvessels,
broader-acting systemic factors are also involved. White matter
lesions and lacunar strokes are associated with increases in
circulating levels of the NO synthase inhibitor asymmetric
dimethylarginine (ADMA) (Notsu et al., 2009; Pikula et al., 2009;
Rufa et al., 2008). ADMA may contribute to the impairment of
NO-dependent vasodilatation in peripheral and cerebral arteries
(Chen et al., 2006; Knottnerus et al., 2009; Pretnar-Oblak et al.,
2006; Stevenson et al., 2010). Furthermore, stiffness of large
vessels and increased pulsatility are associated with reduced
white matter CBF and are strong predictors of leukoaraiosis
and lacunes (Brisset et al., 2013; Tarumi et al., 2011; Webb
et al., 2012), independently of vascular risk factors (Kearney-
Schwartz et al., 2009). These findings implicate loss of large
artery elasticity and increased pulsatile stress on microvessels,
especially those branching directly from the circle of Willis, in
the microvascular damage underlying white matter lesions
(Scuteri et al., 2011). Similar microvascular changes occur also
in other organs, suggesting that small vessel disease in brain
may be themanifestation of a systemic vasculopathy (Thompson
and Hakim, 2009).852 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.Increased Blood-Brain Barrier Permeability
Reflecting another aspect of endothelial dysfunction, alterations
in BBB permeability are also associated with leukoaraiosis and
lacunar stroke (Wardlaw et al., 2013b; Yang and Rosenberg,
2011). Several lines of evidence indicate that the BBB is
disrupted in the course of the disease. First, the plasma protein
albumin is increased in the CSF of patient with VCI, reflecting
BBB breakdown (Candelario-Jalil et al., 2011). Second, plasma
proteins, including complement, fibrinogen, albumin, and immu-
noglobulins are detected in astrocytes in white matter lesions
(Akiguchi et al., 1998; Alafuzoff et al., 1985; Simpson et al.,
2007; Tomimoto et al., 1996). Third, the permeability to MRI
tracers is increased in white matter lesions (Hanyu et al., 2002;
Taheri et al., 2011; Wardlaw et al., 2009) and in normal appearing
white matter (Topakian et al., 2010). The latter finding suggests
that the BBB disruption could precede white matter injury and
contribute to its development. BBB leakiness in white matter
was found in lacunar strokes, but not cortical strokes (Wardlaw
et al., 2008), raising the possibility of a specific association
with small vessel disease of the deep white matter.
Several factors could contribute to the BBB disruption
(Rosenberg, 2012). Hypoxia-ischemia, which has been demon-
strated in white matter lesions, is well known to damage endo-
thelial cells leading to increased BBB leakage in vitro (Al Ahmad
et al., 2012). In vivo, hypoperfusion produced by bilateral carotid
stenosis in rat increases BBB permeability (Ueno et al., 2002).
In a similar model, the BBB alteration was found to be due to
MMP9 production by oligodendrocyte precursors, which are
increased in ischemic white matter injury in rodent models
(Seo et al., 2013) and in patients with VCI (Candelario-Jalil
et al., 2011). In stroke prone spontaneously hypertensive rats,
which have a strong vascular risk factor profile, a high salt diet
induces fast-developing vasculopathy with BBB leakage that
leads to ischemic injury in the absence of arterial occlusions
(Schreiber et al., 2013). This finding indicates that chronic BBB
disruption has the potential of induce ischemic damage. Indeed,
vascular risk factors, and the associated oxidative stress and
vascular inflammation also alter BBB permeability and could
play a role.
Oxidative Stress and Inflammation
Pathological studies have shown markers of oxidative stress
(isoprostanes) and inflammation (cytokines and adhesion
molecules) in the damaged white matter associated with VCI
(Back et al., 2011; Candelario-Jalil et al., 2011; Fernando et al.,
2006). Furthermore, microglial activation and reactive astrocytes
are also present in the lesions (Akiguchi et al., 1998; Simpson
et al., 2007; Tomimoto et al., 1996) (Figure 6). Markers of
endothelial activation, hemostasis, inflammation, and oxidative
stress are also upregulated in blood, consistent with more
widespread effects in the systemic circulation (Gallacher et al.,
2010; Knottnerus et al., 2010; Markus et al., 2005; Rouhl et al.,
2012a; Shibata et al., 2004; Xu et al., 2010) (Figure 6). The
mechanisms of these responses have not been fully elucidated,
but several factors may play a role. Cerebral hypoperfusion
is associated with white matter inflammation and oxidative
stress in rodent models (Dong et al., 2011; Huang et al., 2010;
Ihara et al., 2001; Juma et al., 2011; Masumura et al., 2001;
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ia-ischemia is sufficient to trigger these responses. Vascular risk
factors for VCI, such as hypertension, insulin resistance, and
diabetes, lead to vascular oxidative stress and inflammation,
both in animal models and in humans (Cohen and Tong, 2010;
Iadecola and Davisson, 2008; Yates et al., 2012), which, in
turn, impair the factors regulating the cerebral circulation (Faraci
et al., 2011). Thus, functional hyperemia and endothelium
dependent responses are attenuated in models of aging, hyper-
tension, and diabetes (Ergul, 2011; Kazama et al., 2004; Park
et al., 2007), whereas the ability of the vessels to adjust cerebral
perfusion in response to changes in blood pressure (autoregula-
tion) is blunted in patients with diabetes or hypertension (Kim
et al., 2008b; Novak et al., 2003). Such neurovascular dysfunc-
tion would aggravate the CBF reduction in critically perfused
deep white matter regions and contribute to the white matter
damage. Accordingly, scavenging of free radicals or approaches
to suppress inflammation counteract white matter damage and
behavioral deficits in rodent models of cerebral hypoperfusion
(Dong et al., 2011; Kim et al., 2008a; Maki et al., 2011; Ueno
et al., 2009; Wakita et al., 2008; Wang et al., 2010; Washida
et al., 2010; Zhang et al., 2011). NADPH oxidase, a multiunit
enzyme particularly enriched in cerebral blood vessels (Miller
et al., 2005), has emerges as an important source in vascular
oxidative stress in aging, hypertension, hyperlipidemia and dia-
betes (Faraci et al., 2011), and inhibition or genetic inactivation
of this enzyme has been shown to ameliorate the vascular
dysfunction (Drummond et al., 2011). Extravasation of plasma
proteins, due to the BBB alterations, is also likely to play a
role, since fibrinogen, immunoglobulins, and complement are
potent activators of inflammation and free radical production
(Crehan et al., 2013; Davalos and Akassoglou, 2012; Yoshida
et al., 2002). In particular, fibrinogen extravasation activates
inflammatory pathway through its interaction with integrin
(CD11b/CD18) and non-integrin receptors (TLRs), leading to
activation of microglia and astrocytes (Davalos and Akassoglou,
2012; Davalos et al., 2012) (Figure 6). As discussed next, inflam-
mation and oxidative stress have also deleterious effects on the
trophic interaction among the cells of the neurovascular unit.
Trophic uncoupling
ROS and inflammation suppress the prosurvival action of endo-
thelial cells on neurons by reducing BDNF levels, an effect medi-
ated by impairing integrin linked kinase signaling (Guo et al.,
2008). In models of diabetes, advanced glycation end-products
lead to MMP9 secretion by endothelial cells and cleavage of the
ectodomain of the BDNF receptor TRKB on neurons, reducing
neurotrophic signaling (Navaratna et al., 2013). Owing to their
trophic support of vascular cells, dysfunction and damage to
neurons and glia is associated with endothelial cell atrophy
and microvascular rarefaction (Brown and Thore, 2011). Sys-
temic factor also play a role in the mechanisms of trophic uncou-
pling. EPC are reduced by stroke risk factors (Hill et al., 2003) and
predict cardiovascular morbidity and mortality (Werner et al.,
2005). EPC are reduced in age associated white matter lesions,
the reduction correlating with lesion burden (Jickling et al., 2009).
In addition, EPC may be less functionally competent in patients
with vascular risk factors and stroke. For example, the abilityof colony forming units, a subset of EPC, to form vascular tubes
in a matrigel assay is impaired patients with large artery athero-
sclerosis or lacunar stroke (Chu et al., 2008). Interestingly, EPC
colony forming units are also reduced in AD patients, in whom
the magnitude of the reduction correlates with the degree of
cognitive impairment (Lee et al., 2009). Angiogenic T cells are
reduced in patients with vascular risk factors (Hur et al., 2007;
Weil et al., 2011), and in hypertensive patients with small vessels
disease (Rouhl et al., 2012b). Furthermore, angiogenic T cells
migration in vitro is positively correlated with preservation of
endothelium-dependent vasodilatation in patients with cardio-
vascular risk factors (Weil et al., 2011), highlighting their protec-
tive role in vascular function. These findings, raise the possibility
that vascular risk factors suppress the production of angiogenic
T cells, reduce the repair potential of EPC, and contribute to
the microvascular degeneration underlying leukoaraiosis and
lacunar stroke. Accordingly, capillary density is reduced not
only at lesioned sites, but also in normal appearing white
matter in patients with VCI (Brown et al., 2007). Vessels devoid
of endothelium (string vessels) are often observed, reflecting a
failure of endothelial repair, possibly due to EPC dysfunction or
loss of neuron and/or glial-derived growth factors.
Lesions of white matter tracts also lead to distant effects re-
sulting from loss of trophic support at their site of termination.
Leukoaraiosis is associated with focal cortical thinning espe-
cially in frontal cortex, a finding correlated with executive
dysfunction (Seo et al., 2012). Focal cortical thinning was also
observed in a prospective study of patients with CADASIL
subsequent to a subcortical infarct (Duering et al., 2012), indi-
cating a causal link between white matter lesions and cortical
atrophy. These processes are likely to play a role in the progres-
sive cerebral atrophy observed in patients with leukoaraiosis,
who experience a brain volume loss of 1% per year, twice that
of age matches controls (Nitkunan et al., 2011). However, it
has not been established whether white matter lesions cause
the atrophy independently of age and other risk factors (Appel-
man et al., 2009; 2010). Trophic interactions are also critically
involved in the demyelination and remyelination associated
with leukoaraiosis, which are examined next.
Demyelination and Remyelination
One of the consequences of the oxidative and proinflammatory
environment induced by hypoperfusion and BBB breakdown
is damage to the myelin sheet and demyelination. Myelination
allows axons to conduct 100 times faster, and reduce energy
expenditures by restricting the depolarization of the axonal
membrane to the Na+ channel rich Ranvier nodes (Nave,
2010b). Some of the energy saving afforded by myelination is
offset by the cost of maintaining the resting potential of oligo-
dendrocytes, which is estimated to be high (Harris and Attwell,
2012). Loss of myelin has important consequences for the white
matter tracts. In addition to the brain dysfunction caused by
slowing down the transmission of axon potentials, demyelination
threatens the integrity of the axons and leads to axonal loss
(Franklin and Ffrench-Constant, 2008; Matute and Ransom,
2012). Several factors contribute to the demise of the axons.
Oligodendrocytes release growth factors, such as IGF-1 and
glial cell-derived neurotrophic factor that support the survivalNeuron 80, November 20, 2013 ª2013 Elsevier Inc. 853
Figure 7. Potential Mechanisms of Failure to Remyelinate the
Damaged White Matter
Inflammation-, oxidative-stress-, and hypoxia-induced demyelination. OPC
proliferate to attempt remyelination. High molecular weight hyaluronic acid
(HMW-HA) produced by reactive astrocytes is cleaved by the hyaluronidase
PH20 generating digestion products that inhibit OPC maturation through
mechanisms involving TLR2 and 4 and GSK3b. The resulting OPC maturation
arrest prevents efficient remyelination.
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axons of trophic support and increases their vulnerability. In
addition, demyelination exposes the axons to the deleterious
effects of cytokine and free radicals in the hypoxic white matter,
which may impair axonal energy production leading to failure of
the Na+/K+ ATPase. The resulting accumulation of intracellular
Na+ reverses the operation of the Na+/ Ca2+ exchanger, resulting
in intracellular Ca2+ accumulation (Matute and Ransom, 2012;
Stys et al., 1992). Furthermore, the adaptive upregulation of
voltage-dependent Na+ channels (VNa+) in the denuded inter-
nodal axoplasm, attempting to preserve impulse propagation
in demyelinated axons, leads to Na+ entry and aggravates the
energy deficit and Ca2+ overload. Upregulation of VNa+1.2 chan-
nels increases the activity of the Na+/K+ ATPase, stressing
further the energy budget of themarginally perfusedwhitematter
(Trapp and Stys, 2009). In turn, excess intracellular Ca2+ acti-
vates protease dependent processes that lead to microtubule
fragmentation and perturbation of axonal flow (Franklin and
Ffrench-Constant, 2008; Matute and Ransom, 2012).
Attempts to remyelinate are present in the damaged white
matter in leukoaraiosis (Jonsson et al., 2012). Oligodendrocytes
are responsible for the formation and maintenance of the myelin
sheet. A large pool of oligodendrocyte progenitor cells (OPC)
is present in the brain, which goes through several stages of
development before becoming mature and competent to lay
down myelin (Fancy et al., 2011a). However, in demyelinating854 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.diseases, including leukoaraiosis, axons fail to fully remyelinate
(Franklin and Ffrench-Constant, 2008). Several factors are
thought to be responsible (Figure 7). First, OPC in the late stage
of development are particularly susceptible to injury in condi-
tions of chronic hypoxia and oxidative stress existing in the
ischemic white matter (Back et al., 2011; 2002; Fernando et al.,
2006; French et al., 2009). Oligodendrocytes are also suscepti-
ble to damage caused by extracellular ATP, which increases in
hypoxia-ischemia, through activation of the P2X7 purinergic re-
ceptors (Domercq et al., 2010). Second, withdrawal of trophic
support from damaged endothelial cells and astrocytes could
reduce the vitality of the OPC pool and contribute to their demise
in the hypoxic environment of the vulnerable white matter (Arai
and Lo, 2010). Third, failure to remyelinate could be related to
an arrest in OPC maturation. OPC are abundant in areas of
leukoaraiosis, which are enriched with hyluronan (HA), a high
molecular weight glycosaminoglycan produced by reactive as-
trocytes and other cells (Back et al., 2011). HA is a component
of the matrix and is involved in neurodevelopment promoting
neuronal migration (Sherman and Back, 2008). In white matter
lesions, HA is degraded by the hyaluronidase PH20 and its
cleavage products inhibit the maturation of OPC into oligoden-
drocytes capable of myelination (Preston et al., 2013) (Figure 7).
Dysregulation of theWnt signaling pathway could also play a role
in the OPC developmental arrest (Fancy et al., 2011b). In addi-
tion, OPC produce MMP9, which, as seen in the previous
sections, promotes BBB breakdown perpetuating the cytotoxic
milieu underlying demyelination (Seo et al., 2013).
Putting It All Together
The evidence reviewed above suggests a convergence of
pathogenic factors on cerebral blood vessels, which in turn
leads to white matter damage (Figures 6 and 7). Oxidative
stress-induced endothelial dysfunction caused by risk factors
is most likely an early event leading to white matter damage.
Endothelial dysfunction has two major pathogenic conse-
quences: reductions in resting CBF in the marginally perfused
white matter, and alterations in the permeability of the BBB.
In turn, hypoperfusion and BBB disruption lead to additional
oxidative stress by inducing tissue hypoxia and by extravasa-
tion of plasma proteins, such as fibrinogen. Tissue edema re-
sulting from increased BBB permeability may exacerbate these
alterations by compressing blood vessels and reducing CBF
further. Tissue hypoxia and oxidative stress activate inflamma-
tory pathways through NFkb-dependent transcription, leading
to production of cytokines and adhesion molecules in vascular
cells, reactive astrocytes and activated microglia. Hypoxia,
inflammation and oxidative stress damage oligodendrocytes
and leads to trophic uncoupling in the neurovascular unit,
which, in turn, contribute to the damage to vascular cells and
oligodendrocytes. Oligodendrocyte damage, oxidative stress
and inflammation lead to demyelination and attempted remye-
lination through OPC proliferation. Developmental arrest of
OPC, due to HA degradation products, leads to accumulation
of these cells which secrete MMP9 and worsen the BBB
impairment (Figure 7). Once demyelination occurs, the
increased energy requirement of the denuded axons aggra-
vates the hypoxic stress of the tissue, leading to a vicious circle
Neuron
Reviewthat perpetuates these pathogenic processes and exacerbates
the tissue damage.
Is Hypoperfusion Also Involved in Inherited and
Autoimmune White Matter Diseases?
There is emerging evidence that reduced cerebral perfusion
may contribute to other diseases characterized by white matter
damage. Multiple sclerosis (MS) is the prototypical neuroinflam-
matory disease in which demyelination is thought to be related
to a T cell mediated autoimmune attack on myelin (McFarland
and Martin, 2007). However, in MS patients CBF is reduced in
the normal appearing white matter (Law et al., 2004), as well
as in the gray matter (D’haeseleer et al., 2011). In contrast, in
active lesions displaying BBB disruption CBF is increased,
consistent with vasodilatation caused by inflammation (D’hae-
seleer et al., 2011). The reduction in CBF in the normal white
matter could be caused by a primary vascular dysfunction path-
ogenically linked to the disease process, or could be secondary
to loss of white matter elsewhere, due to distal Wallerian degen-
eration, or reduced synaptic activity (De Keyser et al., 2008).
Studies in which CBF measurements in the normal appearing
white matter were coupled to diffusion tensor imaging, revealed
that the reductions in CBF are associated with restricted diffu-
sion and not with increased fractional anisotropy, as anticipated
if the CBF changes were secondary to Wallerian degeneration
(Saindane et al., 2007). Although the possibility that the reduc-
tion in CBF is secondary to reduced local synaptic activity
has not been ruled out, the fact that the hypoperfusion is
normalized by an endothelin receptor antagonist suggest a pri-
mary vascular cause (D’haeseleer et al., 2013). Consistent with
the hypoperfusion hypothesis, HIF-1a and dependent genes
are upregulated in normal appearing white matter (Graumann
et al., 2003).
Reductions in white matter CBF has also been found X-linked
adrenoleukodystrophy (ALD), a disease caused by mutations in
ABCD1, which encodes a peroxisomal membrane transporter
protein, leading to accumulation of very long chain fatty acids
in brain, spinal cord and adrenal glands (Moser et al., 2000). In
its infantile form, the disease starts between 4 and 8 years
of age and is characterized by a progressive cognitive decline
associated with rampant inflammatory demyelination of the
whitematter (Moser et al., 2000). BBB alterations predict disease
progression (Melhem et al., 2000). Cerebral blood volume,
assessed by susceptibility contrast MRI (Musolino et al., 2012),
or CBF, assessed by single photon emission tomography
(al Suhaili et al., 1994), is reduced in the normal appearing and
abnormal white matter. The mechanisms of the white matter
hypoperfusion remain to be defined. Reductions in CBF prior
to white matter damage were also observed in a patient with
Alexander disease, a rare childhood disease caused by a domi-
nant mutation of the GFAP gene (Ito et al., 2009).
It is noteworthy that, despite fundamental differences in their
pathogenesis, inherited and autoimmune diseases of the white
matter exhibit cerebrovascular alterations before pathology
develops, just like in white matter disease caused by vascular
factors. Thus, hypoperfusion and BBB disruption seem neces-
sary correlates of the process leading to white matter damage
independently of the primary disease cause. Collectively, theseobservations highlight the importance of neurovascular factors
in maintaining white matter health.
Overlap between Vascular and Neurodegenerative
Dementia
The realization that most cases of dementia have mixed patho-
logical features has raised the intriguing possibility that vascular
factors play role in AD and other neurodegenerative diseases.
As discussed in the section on ‘‘Mixed lesions,’’ AD brains
have a wide variety of vascular lesions, suggesting a potential
pathogenic interaction between vascular factors and AD.
However, since cerebrovascular diseases and AD are common
in the aged, the coexistence of the two pathologies could
simply be coincidental (Hachinski, 2011). The overall effect on
cognition would results from the combined burden of vascular
and neurodegenerative pathology, according to an additive
model. Alternatively, vascular disease could promote AD and
vice-versa, resulting in a reciprocal interaction amplifying their
pathogenic effects. The cognitive impact of vascular and AD
neuropathology depends on the severity of the AD pathology
and location of the vascular lesions (Gold et al., 2007). In
advanced cases of AD, vascular lesions do not seem to have a
major influence on the progression of the cognitive deficits,
suggesting the AD pathology is the major driver of the cognitive
dysfunction (Chui et al., 2006; Jellinger, 2001). On the other
hand, in older individuals with moderate AD pathology subcor-
tical vascular lesions are a major determinant of the expression
of the dementia (Esiri et al., 1999; Schneider et al., 2007b;
Snowdon et al., 1997).
Cerebrovascular Factors and AD
Cerebrovascular function is reduced in patients with early AD or
at risk for AD (Claassen et al., 2009; Gao et al., 2013; Luckhaus
et al., 2008; Mentis et al., 1996; Niedermeyer, 2006; Ruitenberg
et al., 2005; Sabayan et al., 2012; Tanaka et al., 2002), impli-
cating reduced cerebral perfusion in the pathobiology of the
disease (Iadecola, 2004). Conversely, some studies (Jendroska
et al., 1995; Ly et al., 2012), but not others (Aho et al., 2006; Mas-
taglia et al., 2003), have reported increased amyloid deposition
in stroke patients, implicating that ischemia promotes AD pathol-
ogy. Furthermore, AD and cerebrovascular diseases may have
common risk factors, such as hypertension, insulin resistance,
diabetes, obesity, hyperhomocystinemia, hyperlipidemia, etc.
(Craft, 2009; Fillit et al., 2008; Honjo et al., 2012; Purnell et al.,
2009). However, the correlation was most evident when the
risk factors were considered together and not individually
(Chui et al., 2012). Furthermore, the correlation was strongest
for vascular dementia and weakest for AD, suggesting that
vascular risk factors may independently increase the likelihood
of dementia without exacerbating AD pathology (Chui et al.,
2012). In contrast, studies that have prospectively evaluated
representative patients cohorts with confirmation of the clinical
diagnosis at autopsy failed to establish a link between the
burden of AD pathology and vascular risk factors (Chui et al.,
2012). It is, therefore, conceivable that in cases in which AD
was diagnosed clinically there might have been a component
of vascular pathology. New imaging and CSF biomarkers for
the in vivo diagnosis of AD may provide additional insights intoNeuron 80, November 20, 2013 ª2013 Elsevier Inc. 855
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et al., 2012; Haight et al., 2013; Purnell et al., 2009).
Vascular Effects of Ab
Mounting evidence that Ab has powerful vascular effects also
suggests a link between AD and vascular disease. Ab140
constrict isolated cerebral and systemic blood vessels (Niwa
et al., 2001; Paris et al., 2003; Thomas et al., 1996), whereas
application of Ab140 to the exposed cerebral cortex of mice
reduces CBF and impairs the increase in CBF induced by
endothelium-dependent vasodilators and functional hyperemia
(Niwa et al., 2000a; 2000b). Similarly, functional hyperemia,
endothelium-dependent responses and autoregulation are pro-
foundly impaired in young mice overexpressing mutated forms
of APP, in which brain Ab is elevated, but there are no plaques,
behavioral alterations, or reductions in resting glucose utilization
(Niwa et al., 2000b; 2002; Tong et al., 2012). These data suggest
that the cerebrovascular effects of Ab are not attributable to
CAA or amyloid plaques, and are not a consequence of
neuronal energy hypometabolism. APP-overexpressing mice
have increased brain damage following occlusion of the middle
cerebral artery (Koistinaho et al., 2002; Zhang et al., 1997), an
effect in part related to poor collateral circulation due to vascular
dysregulation (Zhang et al., 1997). The vascular alterations
induced by Ab are abrogated by overexpression of the ROS
scavenging enzyme superoxide dismutase or deficiency of the
NADPH oxidase subunit NOX2 (Iadecola et al., 1999; Park
et al., 2005; 2008), implicating ROS produced by the enzyme
NADPH oxidase in the vascular dysfunction. The mechanisms
of NADPH oxidase activation involve the Ab-binding scavenger
receptor CD36 (Park et al., 2011). Aged APP mice deficient in
CD36 are protected from cerebrovascular alterations and
behavioral deficits, effects associated with reduced CAA
compared to controls, but no reduction of amyloid plaques
(Park et al., 2013b). Thus, CD36, which is located in vascular
and perivascular cells, may contribute to the accumulation of
Ab in cerebral blood vessels.
Ab Production and Clearance
Hypoperfusion and hypoxia caused by vascular insufficiency
may also facilitate Ab production by activating the APP cleav-
age enzyme b-secretase (Kitaguchi et al., 2009; Sun et al.,
2006; Tesco et al., 2007; Wen et al., 2004a). Cerebral ischemia
promotes amyloid plaque formation (Garcia-Alloza et al., 2011;
Kitaguchi et al., 2009; Okamoto et al., 2012), and tau phos-
phorylation (Koike et al., 2010; Wen et al., 2007; 2004b). The
vascular effects of Abmay also impair the clearance of the pep-
tide, a key factor in brain Ab accumulation in sporadic AD
(Mawuenyega et al., 2010). The vascular pathway is estimated
to be a major route of removal of Ab from the brain (Castellano
et al., 2012; Shibata et al., 2000). Brain Ab is transported along
the perivascular pathway draining into the cervical lymphnodes
(Carare et al., 2013; Iliff et al., 2013). In addition, Ab is cleared
from the brain through a transvascular transport system
involving LRP-1 (Shibata et al., 2000), a protein that acts in con-
cert with P-glycoprotein, ApoE, ApoJ, and a2-macroglobulin to
regulate brain Ab homeostasis (Zlokovic, 2008). Interestingly,
ApoE4, a major genetic risk factor for AD, leads to BBB disrup-856 Neuron 80, November 20, 2013 ª2013 Elsevier Inc.tion through a proinflammatory pathway involving cyclophilin A
in pericytes (Bell et al., 2012). Activation of this pathway causes
MMP-9-mediated degradation of endothelial tight junctions
and basement membrane proteins, as shown in human
ApoE4 targeted replacement mice (Bell et al., 2012). ApoE4
positive individuals may develop a similar age-dependent
BBB breakdown prior to cognitive decline (Halliday et al.,
2013). In patients with vascular risk factors, such as hyperten-
sion, sedentary life style, or ApoE4 genotype, there is a greater
tendency for amyloid accumulation (Head et al., 2012; Rodrigue
et al., 2013), whereas amyloid accumulation is reduced in pa-
tients who exercise regularly (Liang et al., 2010). Experimental
studies indicate that this clearance mechanism is altered in
the presence of vascular dysfunction and damage, contributing
to parenchymal and vascular Ab accumulation (Deane et al.,
2004; Park et al., 2013b). In particular, suppression of LRP1
in vascular smooth muscle cells due to upregulation of serum
response factor and myocardin, is a key factor in the clearance
impairment (Bell et al., 2009). Collectively, these observations
suggest a link between cerebrovascular health and brain Ab
clearance.
These lines of evidence suggest that AD is frequently associ-
ated with cerebral macro- and micro-vascular pathology, which
can contribute to the expression of the dementia. Vascular risk
factors can increase amyloid accumulation and the risk of
clinically defined AD. The vasoactivity of Ab and the influence
of cerebral perfusion on APP processing and Ab clearance
suggest that cerebral blood vessels can have a role the accu-
mulation of Ab in the brain parenchyma and cerebral blood
vessels. Preliminary evidence suggests that control of vascular
risk factors reduces vascular lesions in AD (Richard et al.,
2010), and may delay disease progression (Deschaintre
et al., 2009), at least early in the disease course (Richard et al.,
2010). Although replication in representative cohorts in which
AD is confirmed pathologically or with biomarkers is needed,
these observations provide initial evidence that improving
vascular health may also help in AD.
Prospects for Prevention and Therapy
The development of treatments for VCI has been hampered by
the lack of a suitable animal model recapitulating the multifac-
eted features of the disease (Gorelick et al., 2011). Although
several animal models have been developed (Hainsworth et al.,
2012; Lee et al., 2012), the most widely used has been white
matter damage produced by chronic forebrain ischemia (Ihara
and Tomimoto, 2011). These models have demonstrated
that counteracting some of the pathogenic factors, including
chronic ischemia, inflammation, and oxidative stress, reduce
white matter damage and/or behavioral deficits (Dong et al.,
2011; Ihara and Tomimoto, 2011; Maki et al., 2011). Other
approaches have attempted to promote remyelination by
stimulating the survival and differentiation of OPC (Miyamoto
et al., 2010). Despite these positive results in models of hypo-
perfusion-induced white matter damage, there are no FDA
approved treatments for VCI and vascular dementia (Butler
and Radhakrishnan, 2012). Treatment with antioxidants, anti-
inflammatory agents or agents increasing cerebral perfusion
have not led to consistent results (Butler and Radhakrishnan,
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showed a modest cognitive improvement, but the evidence is
not sufficiently strong to justify clinical use (Chen et al., 2013b).
Clinical trials are currently exploring other agents, including
cholinergic stimulants (choline alphoscerate), vasodilators
(udenafil), inhibitor of platelet aggregation (cilostazol) and
delta-9-tetrahydrocannabinol (a complete list can be found at
www.clinicaltrials.gov).
On the other hand, increasing evidence indicates that the
risk of VCI and vascular dementia can be reduced by preven-
tive measures. A study in the UK population suggests that
the prevalence of dementia may be decreasing, a finding
interpreted to reflect the beneficial effects of controlling blood
pressure and other risk factors (Matthews et al., 2013). Indeed,
rigorous blood pressure control reduces white matter damage
and staves off cognitive decline (Sharp et al., 2011; So¨ro¨s
et al., 2013). Physical and mental activity, social engagement,
and a diet rich in antioxidants or polyunsaturated fatty acids
reduce dementia risk (Aarsland et al., 2010; Akinyemi et al.,
2013; Middleton and Yaffe, 2009; Verdelho et al., 2012). There-
fore, controlling vascular risk factors and promoting a healthy
diet, exercise, and mental activity are promising strategies
to reduce VCI. This hypothesis is supported by a study indi-
cating that weight control, a healthy diet, nonsmoking, physical
activity, and keeping total cholesterol, blood pressure, and
fasting glucose at goal levels are associated with better
cognitive performance later in life (Reis et al., 2013). However,
most of the evidence is based on observational studies, which
have not been confirmed by randomized clinical trials of risk
factor modification, stressing the need for further large-scale
studies (Dichgans and Zietemann, 2012; Middleton and Yaffe,
2009).
Conclusions
VCI and vascular dementia are major contributors to age-related
dementing illnesses and comprise a heterogeneous group of
cognitive disorders attributable to vascular causes. Vascular
pathology is also an integral part of AD and other late-life neuro-
degenerative conditions associated with dementia and plays a
defining role in the expression of the cognitive dysfunction.
Despite the diversity of the underlying brain pathology, the
vascular alterations have a similar pathogenic basis, resulting
from hypoperfusion, oxidative stress and inflammation, which
in turn lead to endothelial damage, BBB breakdown, activation
of innate immunity, and disruption of trophic coupling between
vascular and brain cells. The hemispheric white matter, which
is particularly susceptible to the deleterious effects of vascular
risk factors, is a major target of these vascular alterations. The
resulting demyelination and axonal loss play a role in the broad
functional brain changes underlying cognitive impairment and
in the associated cerebral atrophy. This chain of events high-
lights the critical role that vascular cells play in the maintenance
of the health of neurons, glia, and myelin.
However, several fundamental questions remain to be
addressed. The predilection of the vascular pathology for the
deep hemispheric white matter, a remarkable constant in condi-
tions as diverse as CADASIL and sporadic white matter disease,
remains incompletely understood. Although its peculiar vasculartopology and precarious blood supply are likely to play a role, the
cellular and molecular bases determining the characteristic
vascular lesions remain to be defined. In particular, how aging
and vascular risk factors interact with the vascular wall to induce
vascular lesions preferentially in the white matter remains un-
clear. The relative contribution of hypoperfusion, BBB damage,
and oxidative stress to vascular and parenchymal damage
remain to be defined. Furthermore, what determines the
pathological diversity, e.g., lacunes, microinfarcts, microhe-
morrhages, etc., and spatial localization of the brain lesions
resulting from similar vascular pathology remain unexplained.
A better understanding of ischemic demyelination and abortive
remyelination is needed. Fundamental questions concerning
the interaction of AD pathology with vascular pathology also
remain unanswered. Studies elucidating the vascular biology of
the white matter and the interaction with risk factors and
AD pathology would be needed to shed light on some of
these issues and provide better insight into potential therapeutic
targets. These mechanistic studies can benefit from the increas-
ing availability of cell-specific conditional genetic models,
viral-based gene delivery methods, and novel approaches for
targeted cell replacement/modification in the brain, e.g., (Gold-
man et al., 2012).
Developing treatments for VCI remains a challenge. In addition
to the lack of predictive animal models to guide target selection,
the heterogeneity of the underlying pathology represents a ther-
apeutic challenge. The role of hypoperfusion, BBB disruption,
oxidative stress, and inflammation is well established in animal
models of white matter damage, but therapies based on these
pathogenic mechanisms have not been successful. Although it
has been difficult to prove that these approaches achieved the
intended effect on cerebral perfusion, ROS production, and
inflammation in the white matter at risk, other considerations
make the development of treatments particularly challenging.
For example, the long preclinical phase of dementia is problem-
atic, since, in VCI as in AD, initiating therapy when patients
become symptomatic may be too late. Furthermore, due to
frequent overlap with AD, the diagnosis of VCI can be chal-
lenging, complicating the choice of the best therapeutic
approach (Wang et al., 2012). Novel imaging modalities,
including amyloid and tau imaging, as well as high-resolution
MRI, will go a long way in addressing some of these challenges
and will make it possible to characterize the pathology in vivo
with an unprecedented spatial, temporal, and morphological
accuracy. At the same time, these approaches offer the prospect
of developing new biomarkers that will be critical for identifying
patients at risk, staging the progression of the disease, and
assessing therapeutic efficacy.
Considering that mixed dementia is the most common
cause of dementia in the elderly, it has become increasingly
important to harmonize basic science, translational, and clinical
approaches in AD and vascular dementia. Thus, the impact
of both pathologies should be considered, independently of
whether their contribution is additive or synergistic. In the
absence of effective therapies, promoting and maintaining
vascular health seems critical to prevent both the vascular and
neurodegenerative components of the disease and is probably
the best possible course of action at the present.Neuron 80, November 20, 2013 ª2013 Elsevier Inc. 857
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